SPR as a New Technology in Clinical Research



March 17, 2017

"For more info, visit http://www.bio-rad.com/yt/18/proteonwebinar Infliximab is a chimeric monoclonal antibody that targets tumor necrosis factor-alpha and is used to treat a variety of chronic autoimmune disorders such as rheumatoid arthritis, Crohn's disease and ulcerative colitis. Monitoring serum infliximab concentrations is important in guiding disease management, especially when a patient is not responding well to treatment. Infliximab concentrations can determine if loss of efficacy is due to inadequate dose or to the development of anti-infliximab antibodies. Currently, 3 reference labs offer quantitative infliximab testing. However, the high cost of these tests limits frequency of use. Here, using the ProteOn XPR36, we describe development of a quantitative assay for infliximab in serum, and explore the practicality of using surface plasmon resonance in the clinical lab. http://info.bio-rad.com/ww-ProteonVideoLibrary-LP1.html?WT.mc_id=yt-PFD-ww-X5edxIyVXR0"

Drug Discovery

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.